|
|
|
| |
CRU Organization
Dean, Faculty of Tropical Medicine
Chief, Clinical Trial Project
Staffs
 |
|
| |
|
|
|
|
|
| |
| | |
|
| |
| |
About VTC
> Phase I, II and III HIV-1 vaccine trials in the
VTC
![]()
| |
| |
|
|
|
| |
|
Phase I, II and
III HIV-1 vaccine trials in the
VTC
|
|
|
Vaccine |
Vaccine |
Phase |
No of
participants |
Dose
interval |
Type of
immunity |
Subunit (recom- binant
protein)
|
|
|
|
|
|
|
|
1995
|
I/II |
33 recovering IDUs
|
0, 1, 6 and 12 months
|
Humoral |
gp120/MF59, subtype E antigen alone or
combined with B antigen
|
1997
|
I/II |
370 low risk adults
(99-VTC)
|
0, 1, and 6 months |
Humoral |
gp120/alum, combined subtype B (AIDSVAX® B/E)
|
1998
|
I/II |
92 recovering IDUs and low risk
adults
|
0, 1, 6 and 12 months |
Humoral |
r gp120/alum, combined subtype B (AIDSVAX® B/E)
|
1999
|
III |
2,500 high risk
IDUs
|
0, 1, 6, 12, 18, 24 and 30
months |
Humoral |
|
|
|
|
|
|
|
ALVAC-HIV rgp 120 B/E boost
|
2000
|
I/II |
123 low risk adults
(62-VTC)
|
0, 1, 3 and 6 months
|
Cell mediated +
humoral |
ALVAC-HIV rgp 120 B/E boost
|
2003
|
III |
16,000 low risk adults
|
0, 4, 12 and 24 weeks |
Cell mediated +
humoral |
|
|
2003
|
I/II |
87 healthy adults (29-VTC)
|
0, 4 and 26 weeks |
Cell mediated +
humoral | | |
|
To date, seven projects of phase I/II and phase III HIV-1 vaccine trials, involving thousands of volunteers, have been conducted by the Center, or as one of the collaborators.
<<
Back | | | | |
|
